Short Communication

Adverse drug reactions among patients admitted with infectious diseases at a Brazilian hospital

**Pamela Alejandra Saavedra**[1], **Micheline Marie Milward de Azevedo Meiners**[2], **Luciane Cruz Lopes**[3], **Emília Vitória da Silva**[2], **Dayde Lane Mendonça da Silva**[1], **Elza Ferreira Noronha**[4] and **Maria Inês de Toledo**[1]

[1]. Faculdade de Ciências da Saúde, Universidade de Brasília, Brasília, Distrito Federal, Brasil. [2]. Faculdade de Ceilândia, Universidade de Brasília, Ceilândia, Distrito Federal, Brasil. [3]. Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade de Sorocaba, Sorocaba, São Paulo, Brasil. [4]. Núcleo de Medicina Tropical, Faculdade de Medicina, Universidade de Brasília, Brasília, Distrito Federal, Brasil.

**Abstract**

**Introduction:** Despite the therapeutic benefits of drugs, adverse drug reactions (ADRs) occur. **Method:** We assessed a series of suspected ADRs identified from notifications and intensive monitoring of inpatients from March 2013 to March 2014. **Results:** Skin reactions predominated (31%). Systemic anti-infective agents were implicated in 16 (72%) reactions. Fifteen (68%) ADRs were classified as possible. The implicated drug was not correctly identified by the healthcare team in 12 cases. **Conclusions:** Some reactions were not correctly attributed to the causative drug(s), suggesting that the use of a validated evaluation method can promote successful identification of causal links between ADRs and drugs.

**Keywords:** Adverse drug reactions. Pharmacovigilance. Hospitals.

Drugs are crucial therapeutic tools, and ensuring access to their use is a global priority. However, drugs also carry the risk of adverse reactions. Since the thalidomide tragedy in 1960, countries have sought to implement pharmacovigilance systems and have conducted studies to prevent or minimize adverse drug reactions (ADRs), thereby reducing the huge impact these events can have on morbidity and mortality rates and on healthcare costs[1](2). Questions on whether responses to drugs and the occurrence of ADRs are influenced by factors such as ethnicity remain unanswered, calling for local pharmacoepidemiologic studies to feed the World Health Organization (WHO) notification system in Uppsala. Furthermore, national or regional level data have educational value and can guide the formulation of national level regulatory measures[3](4).

In 2013, the Brazilian Health Surveillance Agency [Agência Nacional de Vigilância Sanitária (ANVISA)] issued regulations to improve patient safety in healthcare services, decreeing that adverse event notifications and monitoring be employed to reduce risks among inpatients[5]. By detecting and evaluating ADR causality — a key procedure in pharmacovigilance — risk-benefit assessment of drugs can be conducted for specific populations, triggering warnings from global pharmacovigilance systems and ultimately reducing exposure risks by adjusting drug dosages[6]. The present study sought to describe the occurrence of ADRs in adults hospitalized with infectious diseases at a Brazilian teaching hospital and to establish causal links with the drugs administered.

Adverse drug reactions identification was based on data collected from suspected ADR notification forms, drug-therapy follow-up reports, medical records, laboratory tests, and hospital prescriptions. The patients included in the study were adults treated by the infectology team of the *Universidade de Brasília* teaching hospital between 1 March 2013 and 31 March 2014. Patients hospitalized for less than 48h and those with no medical records available were excluded. The following data were collected: patient identification; description of suspected ADR; onset and duration of the event; daily dose, administration route, administration period, and rationale for prescription of the implicated drug; other drugs prescribed; protocol followed for ADR management; clinical evolution; and information on re-exposure to the implicated drug. ADR diagnosis was based on the definition proposed by the World Health Organization (WHO), i.e., any harmful or undesirable and unintended response occurring with drugs in dosages typically used in humans for prophylaxis, diagnosis, or treatment of diseases or for altering physiologic functions[1].

The Naranjo algorithm[6] was employed to establish causal links between suspected ADRs and drugs. The descriptions of suspected ADRs were harmonized with the WHO Adverse Drug Reaction Terminology. The approaches adopted by the
multiprofessional team were categorized as drug withdrawal followed by no reaction improvement, drug withdrawal followed by reaction improvement, continued drug administration, dosage modification, and need for symptomatic treatment. Identification of suspected events drew on the following sources: Brazilian National Formulary (Formulário Terapêutico Nacional 2010)(7), Micromedex Solutions (Truven Health Analytics) (8), and Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drugs Reactions and Interactions (9). Investigation of causal links was not limited to the drug initially identified, but extended to other drugs having a possible temporal relationship with the suspected ADR. The organs and physiologic systems affected were identified and all suspected ADRs were categorized as type A or B, according to Rawlins and Thompson(10). The Anatomical Therapeutic Chemical (ATC) classification(11) was applied to categorize the drugs implicated in suspected events.

The study included 113 patients: 67% (n = 76) were men; the mean age was 43 years; and 44% (n = 50), were human immunodeficiency virus (HIV) infected. The mean length of hospital stay was 12 days (Table 1). Fourteen (12%) patients were hospitalized more than once, 15 (13%) had changes in the level of treatment complexity, and four (3.5%) died during the study period. Twenty-two suspected ADRs were identified in 13 (12%) patients (1.7 ADR per patient). The mean length of hospital stay for these patients was 25 days (Table 1). Skin (31%), hepatobiliary (18%), and gastrointestinal reactions (18%) predominated. Pruritus (22%), changes in liver function (13%), and nausea/vomiting (13%) were the most common symptoms experienced. Twenty-one 95%) of the events (were Type A ADRs; one reaction (cutaneous hyperpigmentation related to polymyxin B) was categorized as type B.

The suspected drug was withdrawn in 14 (63%) cases and continued in six (27%); information on ADR management was lacking for two events. Symptomatic treatment was initiated in seven cases (after drug withdrawal in four). Three events required intensive monitoring using laboratory tests. Of the patients affected, 11 (84%) recovered without sequelae and two died of unrelated causes. Fifteen drugs were implicated, ten (66%) of which were systemic anti-infectives (J01, J02, J05) and four (26%) were drugs acting on the central nervous system (N02, N03). Among the anti-infective agents, polymyxin B and sulfamethoxazole-trimethoprim were each connected with four events. Among exposed patients, polymyxin B accounted for most suspected cases (Table 2).

Causal links with the drug initially implicated were established as suspected in 22 events, probable in six (27%), possible in 15 (68%), and uncertain in one (5%). In the six cases having a probable causal link with the drug initially reported (Naranjo scores of 5 or higher), the additional drugs administered had lower scores (possible ADR) (Table 2). In the 15 events with possible causal links, 99 other drugs were administered. The drug initially reported scored higher than the other drugs administered in only one event. In all remaining cases, the other drugs scored the same or higher than that initially reported as causing the reaction.

Fourteen (64%) reactions were identified from notification forms and eight (36%) from clinical records, indicating underreporting of ADRs. Employing both strategies allows ADR frequencies to be more accurately estimated, and entails the surveying of cases during patient follow-up by professionals with pharmacovigilance training. Intensive monitoring and review of medical records were also employed by Menezes et al.(12) Lobo et al.(13) used incentives to promote spontaneous notification, associated with intensive monitoring of medical records and laboratory tests. Miguel et al.(14) compared intensive monitoring with retrospective searching of databases, finding the latter method to be less costly.

In the present study, the ADR incidence was 11.5%. In a systematic review of 29 studies, Cano et al.(15) observed that ADRs occurred in 1.6-41.4% of inpatients, with rates of 1.7-51.8 events per 100 hospitalizations. In another systematic review, Miguel et al.(14) found that ADRs occurred in 16.9% of inpatients, but this rate may have been biased by population heterogeneity and the methods employed. Secondary data from the Brazilian Hospital Information System revealed an ADR prevalence

### Table 1

| Characteristics                                      | All patients | Patients with ADRs |
|------------------------------------------------------|--------------|--------------------|
| Patients enrolled                                    | 113          | 13                 |
| Males n (%)                                          | 76 (67)      | 9 (69)             |
| Age (years: mean ± SD)                               | 43 ± 17.1    | 37 ± 14.3          |
| >60 years (n)                                        | 16           | 1                  |
| HIV-infected (n)                                     | 50           | 5                  |
| On ART (n)                                           | 40           | 3                  |
| Length of hospital stay (days: mean ± SD)            | 12 ± 10.2    | 25 ± 21.7          |
| Length of hospital stay (days: median, range)        | 9 (2–81)     | 19 (2–77)          |

ADR: adverse drug reaction; SD: standard deviation; HIV: human immunodeficiency virus ART: antiretroviral therapy.
TABLE 2
Drugs implicated in suspected ADRs among patients hospitalized for infectious diseases at the *Universidade de Brasília* teaching hospital between March 2013 and March 2014.

| Drug                                      | ATC     | ADRs | Patients affected | Patients exposed | ADRs per exposed patient (× 100) |
|-------------------------------------------|---------|------|------------------|------------------|---------------------------------|
| Sulfamethoxazole + trimethoprim          | J01EE01 | 4    | 4                | 36               | 11.1                            |
| Polymyxin B                              | J01XB02 | 4    | 2                | 2                | 200.0                           |
| Ceftriaxone                               | J01DD04 | 1    | 1                | 31               | 3.2                             |
| Sulfadiazine                              | J01EC02 | 1    | 1                | 9                | 11.1                            |
| Oxacillin                                 | J01CF04 | 1    | 1                | 8                | 12.5                            |
| Fluconazole                               | J02AC01 | 1    | 1                | 30               | 3.3                             |
| Liposomal amphotericin B                 | J02AA01 | 1    | 1                | 7                | 14.3                            |
| Ganciclovir                               | J05AB06 | 1    | 1                | 4                | 25.0                            |
| Atazanavir                                | J05AE08 | 1    | 1                | 7                | 14.3                            |
| Ritonavir                                 | J05AE03 | 1    | 1                | 26               | 3.8                             |
| Tramadol                                  | N02AX02 | 2    | 1                | 16               | 12.5                            |
| Paracetamol                               | N02BE01 | 1    | 1                | 14               | 7.1                             |
| Carbamazepine                             | N03AF01 | 1    | 1                | 5                | 20.0                            |
| Gabapentin                                | N03AX12 | 1    | 1                | 2                | 50.0                            |
| Lactulose                                 | A06AD11 | 1    | 1                | 8                | 12.5                            |

ADR: adverse drug reaction; ATC: anatomical therapeutic chemical classification.

TABLE 3
Evaluation of ADR causality in patients hospitalized for infectious diseases at the *Universidade de Brasília* teaching hospital between March 2013 and March 2014.

| Adverse drug reaction | Suspected drug       | Naranjo score | Causality | Other drugs       | Naranjo score | Causality |
|-----------------------|----------------------|---------------|-----------|--------------------|---------------|-----------|
| Elevated serum creatinine | Polymyxin B | 7          | Probable | Meropenem | 3 | Possible |
| Paresthesia           | Polymyxin B       | 7          | Probable | Amlodipine | 3 | Possible |
| Pruritus              | Polymyxin B       | 5          | Probable | Amlodipine | 3 | Possible |
| Anemia                | Sulfamethoxazole + trimethoprim | 5 | Probable | Prednisone | 3 | Possible |
| Nausea and vomiting   | Ritonavir          | 7          | Probable | -          | - | -        |
| Diarrhea              | Lactulose          | 7          | Probable | Meropenem | 3 | Possible |

ADR: adverse drug reaction; ATC: anatomical therapeutic chemical classification.
of 1.8 per 1,000 hospitalizations. According to the investigators, all inpatients in the sample were at risk, given the widespread use of drug therapy in hospitals.

In the present study, 31% of suspected ADRs affected the skin, while 18% impacted hepatobiliary functions and another 18% altered gastrointestinal functions. Similarly, Menezes et al. found a predominance of cutaneous rash (20%), puritus (13%), and hyperemia (12%) among ADRs, while Rozenfeld et al. reported ADRs predominantly affecting the gastrointestinal tract (55%) and central nervous system (22%). Dermatologic reactions are described as the most frequent type in a number of studies, partially because these ADRs are more promptly identified. In the present study, type A reactions accounted for 95% of the suspected cases. Similar results have been reported elsewhere.

The only reaction classified as type B in the present study was a case of skin hyperpigmentation associated with polymyxin B – a rarely reported ADR.

Of the patients with suspected ADRs, 84% recovered without sequelae and two (16%) died of other causes. Similar results were obtained elsewhere in Brazil. In a study by Noblat et al., the outcomes of ADRs included 90.6% recoveries, 6.1% deaths from other causes, 2.8% unknown outcomes, and 0.7% deaths from ADRs. In an investigation by Rozenfeld et al., 84.1% of patients with ADRs were discharged.

In the present study, an association was found between length of hospital stay and ADR occurrence: patients with longer stays had a greater number of reactions. Involvement of anti-infective agents in the majority of suspected ADRs was an expected feature, as all patients had an infectious disease and there was a high prevalence of immunosuppression. This pattern, however, was not observed for drugs acting on the central nervous system, prescribed for few patients in the present study. A number of studies have reported an association between ADRs and anti-infective agents, as well as between ADRs and drugs acting on the central nervous system.

Using the Naranjo algorithm, most reactions described in the present study were classified as possible. Similar results were found by other investigators. Causality was investigated for all drugs having a temporal relationship with the reaction. Few studies, however, have applied the Naranjo algorithm to additional medications given to patients. In a study by Danza et al., nearly half of ADRs were related to drug interactions, a factor that increases the risks of type A reactions. The Naranjo algorithm proved highly specific, establishing causal links when causality criteria were clearly met – i.e., the algorithm correctly identified patients with high scores (who developed ADRs) and those with low scores (without ADRs). However, when criteria were not readily met or when variables could not easily be distinguished, the algorithm displayed low sensitivity, failing to clearly distinguish causal links. Categorization of a reaction as possible indicated that the healthcare team failed to identify the drugs responsible for the reaction, since the drug initially suspected had a lower score than other medications administered.

In most studies, the number of ADRs identified from notification system databases tends to be low, but can be enhanced by additional techniques, such as intensive monitoring or use of ADR surveillance software. Encouraging healthcare professionals to record iatrogenic events is crucial for obtaining valid data. In a review of ADR prevention methods, Rommers found that participation of a clinical pharmacist in patient visits and use of computer-based prescribing are among the most employed strategies. The relevance of engaging pharmacists in ADR prevention has also been emphasized by other investigators.

The ADR profile identified in the present study and the finding that some of these reactions failed to be correctly attributed to the causative drugs suggest that employing a validated evaluation method promotes the successful identification of causal links between adverse reactions and drugs.

**Ethical considerations**

The study was approved by the Research Ethics Committee of the School of Health Sciences of the Universidade de Brasília (permit 278.787). All data concerning patients and prescribers were kept confidential.

**Conflict of Interest**

The authors declare that there is no conflicts of interest.

**Financial Support**

This study is part of a subproject funded by the Brazilian Health Ministry (bidding process 133/2013).

**REFERENCES**

1. World Health Organization. Department of Essential Drugs and Medicines. The Uppsala Monitoring Centre. The Importance of Pharmacovigilance: safety monitoring of medicinal products. Geneve, Switzerland; 2002. Available at: http://doi.wiley.com/10.1002/0470853093
2. Cano FG, Rozenfeld S. Adverse drug events in hospitals: a systematic review. Cad Saúde Pública 2009; 25 (suppl 3):S360-S372.
3. Eliasson E. Ethnicity and adverse drug reactions: personalised drug treatment is getting closer but will not replace good clinical judgment. BMJ 2006; 332:1163-1164.
4. Organização Panamericana da Saúde/Organização Mundial da Saúde (OPAS/OMS). Monitoração da segurança de medicamentos. Diretrizes para criação e funcionamento de um Centro de Farmacovigilância. Brasília: Organização Panamericana da Saúde; 2005.
5. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Resolução RDC Nº 36 de 25 de julho de 2013. Institui as ações para segurança do paciente em serviços de saúde e dá outras providências. Brasília: Diário Oficial da União. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2013/rdc0036_25_07_2013.html
6. Belhekar MN, Taur SR, Munshi RP. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol 2014; 46:117-120.
7. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Formulário Terapêutico Nacional 2010. 2ª edição. Rename 2010. Série B. Textos Básicos de Saúde. Brasília: Ministério da Saúde; 2010. 1140p.
8. Truven Health Analytics. Micromedex Solutions. Cited 2014 May. Available from: http://www.micromedexsolutions.com/micromedex2/librarian.

9. Aronson JK, editor. Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (6 volume set). 15th edition. Amsterdam: Elsevier; 2006. 4192p.

10. Davies DM, Ferner RE, Glanville H, editors. Davies Textbook of Adverse Drug Reactions. Fifth edition. London: Chapman & Hall Medical; 1998. 971p.

11. World Health Organization. Collaborating Centre for Drug Statistic Methodology. International language for drug utilization research ATC/DDD. Cited 2014 Jul. Available from: http://www.whocc.no/

12. Menezes FG, Nascimento JWL. Monitoramento de eventos adversos em ambiente hospitalar: relato de farmacovigilância, São Paulo. ConScientiae Saúde 2010; 9:582-587.

13. Lobo MGAA, Pinheiro SMB, Castro JGD, Momenté VG, Pranchevicius MCS. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Tox 2013; 14: doi: 10.1186/2050-6511-14-5.

14. Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2012; 21: 1139-1154.

15. Rozenfeld S. Agravos provocados por medicamentos em hospitais do Estado do Rio de Janeiro, Brasil. Rev Saude Publica 2007; 41:108-115.

16. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013; 65:779-808.

17. Noblat ACB, Noblat LAC, Toledo LAK, Santos PM, Oliveira MGG, Tanajura GM, et al. Prevalência de admissão hospitalar por reação adversa a medicamentos em Salvador, BA. Rev Assoc Med Bras 2011; 57:42-45.

18. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens a critical review. J Antimicrob Chemother 2007; 60:1206-1215.

19. Danza A, Cristiani F, Giachetto G. Reacciones adversas a los medicamentos en un servicio de medicina interna del Hospital Universitario. Rev Med Urug 2010; 26:138-144.

20. Rommers MK, Teep-Twiss IM, Guchelaar HJ. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 2007; 16:1129-1135.